Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
Roos
Jonathan C P
JC
Chilvers
Edwin R
ER
Ostor
Andrew J K
AJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001230:Aspergillus / Q000302:isolation & purification; D018893:Bronchoalveolar Lavage; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D008407:Mast Cells / Q000382:microbiology / Q000473:pathology; D008727:Methotrexate / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate